Segantii Capital Management’s Royalty Pharma RPRX Stock Holding History

Segantii Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-285,000	Closed	-$12.4M	–	544
2021 Q1	$12.4M	Hold	285,000	–	–	0.53%	48
2020 Q4	$14.3M	Buy	+285,000	New	+$12.1M	0.66%	39

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCG

Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return

SGA

Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

Segantii Capital Management's RPRX Position: Q2 2021 in Review

Segantii Capital Management sold out of Royalty Pharma (RPRX) in Q2 2021, closing a stake of 285,000 shares — an estimated $12.4M sold.

Segantii Capital Management first reported a position in RPRX in Q4 2020 and held it in 2 quarters. The position peaked at $14.3M in Q4 2020. 236 funds tracked by Wall St. Rank hold RPRX as of Q2 2021.

Segantii Capital Management reported no remaining Royalty Pharma position as of Q2 2021 after selling out during the quarter.
Segantii Capital Management sold 285,000 Royalty Pharma shares in Q2 2021, an estimated $12.4M.
Segantii Capital Management first reported a position in Royalty Pharma in Q4 2020 and held it in 2 quarters.
Segantii Capital Management's Royalty Pharma position peaked at $14.3M in Q4 2020.
236 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2021.

Based on Segantii Capital Management's 13F filing for Q2 2021, filed 6 Aug 2021.